SUNNYVALE, Calif. - 23andMe Holding Co. (NASDAQ:ME), a genetics-led healthcare and therapeutics company, today announced the implementation of a 1-for-20 reverse stock split for its Class A and Class B common stock. The split took effect at 12:01 a.m. EST, with the company's Class A common stock beginning to trade on a split-adjusted basis as the market opened.
The reverse stock split was executed through an amendment to the company's Certificate of Incorporation filed with the Secretary of State of Delaware. This corporate action has resulted in the consolidation of every 20 shares of issued and outstanding Class A and Class B common stock into one share of the respective class. In connection with the reverse stock split, no fractional shares were issued. Stockholders who would have received a fractional share were rounded up to the next whole share.
As a result of the reverse stock split, the total number of 23andMe's issued and outstanding shares has been significantly reduced. Pre-split, the company had approximately 350,292,546 shares of Class A common stock and 166,443,192 shares of Class B common stock. Post-split, these numbers have been adjusted to approximately 17,514,628 and 8,322,160 shares respectively.
The company has also proportionally adjusted the number of shares of Class A common stock subject to outstanding restricted stock unit and stock option awards, as well as the exercise prices for these awards. Similarly, the number of shares authorized for issuance under the company's incentive equity plan and employee stock purchase plan has been reduced in accordance with the 1-for-20 split ratio.
This corporate move is a strategic effort by 23andMe to potentially make its stock more appealing to a broader range of institutional and other investors. However, the company has cautioned that there are risks and uncertainties associated with the reverse stock split, including potential adverse effects on the stock price and the company's ability to meet Nasdaq's minimum bid price requirement for continued listing.
The information for this report is based on a press release statement from 23andMe.
In other recent news, 23andMe has announced a 1-for-20 reverse stock split, reducing the total number of Class A and Class B common shares significantly. The company has also reported a 34% decrease in Q1 2025 revenue, falling to $40 million, primarily due to the termination of a partnership with GSK. However, the company's net loss showed improvement, standing at $69 million compared to the previous year's $105 million. Citi has reiterated a Neutral rating on 23andMe.
The company is also facing potential delisting from Nasdaq due to non-compliance with corporate governance requirements following the resignation of all independent directors over strategic differences with CEO Anne Wojcicki.
In terms of product development, 23andMe has been actively expanding its services, launching a new report aimed at helping individuals understand their genetic predisposition to emotional eating, and teaming up with Mathew Knowles (NYSE:KN) to promote the benefits of genetic testing for identifying personal health risks. Additionally, its subsidiary, Lemonaid Health, introduced a new weight loss program providing access to GLP-1 medications through a monthly subscription model. These are the recent developments shaping the trajectory of 23andMe.
InvestingPro Insights
The recent 1-for-20 reverse stock split implemented by 23andMe Holding Co. (NASDAQ:ME) comes at a time when the company faces significant financial challenges. According to InvestingPro data, 23andMe's stock has experienced a substantial decline, with a 1-year price total return of -69.61% as of the most recent data. This downward trend is further emphasized by the stock trading at just 26.48% of its 52-week high.
InvestingPro Tips highlight that 23andMe is currently not profitable over the last twelve months, with analysts not anticipating profitability this year. This is reflected in the company's financial metrics, including a negative P/E ratio of -3.34 and an operating income margin of -128.25% for the last twelve months as of Q1 2025.
Despite these challenges, 23andMe maintains a strong balance sheet position. An InvestingPro Tip notes that the company holds more cash than debt, which could provide some financial flexibility as it navigates its current difficulties. Additionally, the company's revenue for the last twelve months stands at $199.19 million, although it has experienced a revenue growth decline of -32.67% over the same period.
The reverse stock split appears to be a strategic move to address the stock's poor performance, as another InvestingPro Tip indicates that the stock has taken a significant hit over the last week, with a 1-week price total return of -11.38%. This action may help 23andMe meet Nasdaq's minimum bid price requirements and potentially attract new investors.
For readers interested in a more comprehensive analysis, InvestingPro offers 11 additional tips for 23andMe, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.